Dr Vincent Geldhof from AZ Klina in Brasschaat presented a multicenter study on real-world treatment practices for lung cancer patients receiving immune checkpoint inhibitors. The study analyzed 597 variables, mapping them to standardized terminologies like SNOMED-CT, and established OMOP-CDM databases. Machine learning and natural language processing were used to process records and algorithm outputs were validated against a physician-generated standard. This approach provides valuable insights into immune checkpoint inhibitor usage in lung cancer treatment, advancing oncology research and patient care.